Circulating tumor cells and prostate cancer prognosis
Authors:
Otakar Čapoun 1; Viktor Soukup 1; Veronika Mikulová 2; Markéta Jančíková 2; Hana Honová 3; Katarína Kološtová 4; Tomáš Zima 2; Tomáš Hanuš 1
Authors‘ workplace:
Univerzita Karlova v Praze, 1. lékařská fakulta a VFN, Urologická klinika
1; Univerzita Karlova v Praze, 1. lékařská fakulta a VFN, Ústav lékařské biochemie a laboratorní diagnostiky, Laboratoř klinické imunologie a alergologie
2; Univerzita Karlova v Praze, 1. lékařská fakulta a VFN, Onkologická klinika
3; Univerzita Karlova v Praze 3. lékařská fakulta, Oddělení nádorové biologie
4
Published in:
Čas. Lék. čes. 2014; 152: 72-77
Category:
Review Article
Overview
Prostate cancer (PC) is the most common malignant disease in men. Prognosis of patients with metastatic PC is generally unfavourable; however there are significant differences in survival at this stage of the disease. The definition of prognosis is essential for the selection of therapy, respecting an individual risk. In recent years, the association between circulating tumor cells (CTC) detection and response to PC treatment has been widely investigated. Detection of CTC is based on a metastatic process theory and uses well-known tumor-specific antigens on the cell surface. Individual methods assess CTC with different sensitivity and are not yet efficient at the localised PC stage. Only the method of immunomagnetic separation and semi-automatic visualisation (CellSearchTM) has been validated and approved for the use in the PC management. Assessment of the CTC count directly correlates with the prognosis of patients with castration-resistant PC. Change in the CTC count during the therapy also considerably improves risk estimation and represents a marker of overall survival. New methods of CTC cultivation and gene profiling may contribute to individualisation of the treatment similarly to breast cancer. The authors present a review article about theory, methods of detection and clinical use of CTC in castration-resistant PC.
Keywords:
prostate cancer – circulating tumor cells – prognostic parameters – biomarker
Sources
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.
2. Mužík J, Dušek L, Babjuk M, Kubásek M, Fínek J, Petruželka L. Uroweb – webový portál pro analýzu a vizualizaci epidemiologie, diagnostiky a léčby urologických malignit [online]. Masarykova univerzita, Brno, 2013 [cit. 2013-05-11]. Dostupný z: http //www.uroweb.cz. ISSN 1804-6371. Verze 1.6d.
3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59(4): 572–583.
4. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death, The Medical Journal of Australia 1869; 14: 146–147.
5. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571–573.
6. Patel LR, Camacho DF, Shiozawa Y, et al. Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol 2011; 7(11): 1285–1297.
7. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70(14): 5649–5669.
8. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139(5): 871–890.
9. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17(12): 3903–3912.
10. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21(7): 1232–1237.
11. Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010; Article ID 617421.
12. de Bono JS, Scher HI, Montgomery BR, et al. Circulating tumor cells predict survival benefi t from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14(19): 6302–6309.
13. Davis JW, Nakanishi H, Kumar VS, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 2008; 179(6): 2187–2191.
14. Murray NP, Reyes E, Orellana N, et al. Secondary Circulating Prostate Cells Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease. Scientific World Journal 2013; 762064.
15. Tombal B, Van Cangh PJ, Loric S, Gala JL. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003; 56(3): 163–170.
16. Mikulová V, Jančíková M, Čapoun O, et al. Cirkulující nádorové buňky u pacientů s kastračně rezistentním karcinomem prostaty jako součást individualizace systémové léčby. Onkologie B (2012): B34 (ročník 6.), 29. až 30. listopadu 2012.
17. Pesta M, Fichtl J, Kulda V, et al. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res 2013; 33(5): 2239–2243.
18. Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14(4): R118.
19. Mikulová V, Kološtová K, Zima T. Methods for detection of circulating tumour cells and their clinical value in cancer patients. Folia Biol (Praha) 2011; 57(4): 151–161.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Some immunological properties of female saliva and its effect on sperm motility
- Platelets in the pathogenesis of solid tumors
- Potential interactions between drugs and dietary supplements
- Circulating tumor cells and prostate cancer prognosis